On April 24, FDA issued a warning letter to contract testing laboratory International Trading Pharm Lab Inc., located in Paterson, N.J. Consumer Safety Officer Niketa Patel conducted the initial inspection October 15-29, 2019. This inspection resulted in a 483 and an Official Action Indicated classification due to data integrity issues.

Barbara Unger provided highlights in her May 26 blog post; a more detailed summary is below. 

[NOTE: Looking to avoid a data integrity citation in a 483?  We can help!  Click here for a free 483 Observation Report using “data integrity” as your keyword.]

Get your 483 Observation Report

FDA cited a number of quality issues at the site to the point of recommending the company hire a qualified consultant “to assist in your remediation.” In addition, FDA also encouraged the company to review its guidance on Quality Agreements for contract manufacturing organizations in addition to a Q&A on data integrity

Why make these recommendations? For one, the Warning Letter points to significant CGMP deviations concerning APIs, explaining that the API tested could be considered adulterated under the requirements of the Food, Drug, and Cosmetic Act. A number of these included data integrity violations.

Data Integrity Tops Citation List

The first item highlighted in the Warning Letter explicitly cited failures by the Quality Unit to appropriately test the drugs and report the results to clients. In particular, the inspectors noted that several out-of-specification results from chromatographic tests were not included in an investigation. These were also not communicated to the client. A review of an onsite OOS investigation conducted by the firm in 2017 found that one out of four samples was retested 14 hours following initial testing. This retest data was not included in the analyst’s notebook. In fact, it was not documented as part of the investigation. The Quality Unit was unaware the testing even occurred—a clear data integrity failure. 

Another sample was also tested a second time but labeled “Experimental.” Again, this was not included as part of the firm’s official OOS investigation. Unsurprisingly, FDA felt concerned these findings could be indicative of “testing into compliance.”

In response to the 483 issued, the company assured that auditors would check to ensure no retesting occurs. The Warning Letter explained that this was “inadequate because you did not conduct a review of electronic chromatographic data to determine the extent and impact of this practice.” In fact, the updated procedure failed to firmly state “that sample injections cannot be used to verify the system equilibrium.”

FDA requested the company:

  • Update the procedure for chromatography analysis to explicitly state that trial injections will not be conducted and only qualified reference standards be used to verify chromatography analysis equipment
  • Inform FDA of any actions and client communications due to “experimental” injection results 
  • Provide FDA with a remediation plan for the Quality Unit

FDA felt concerned these findings could be indicative of ‘testing into compliance’

More Issues with OOS Investigations Pop Up

Investigations of OOS results were also closed without justification. In one example, data on solution stability was found to be lacking. The company responded to this point on the initial 483 by stating that the client had refused to authorize stability studies of that particular solution. Naturally, FDA pointed out that contract testing laboratories are responsible for CGMP operations regardless of any client demands or lack thereof. 

FDA cited this instance as a significant failure to follow procedures for investigating deviations/batch API failures. In the Warning Letter, FDA requested the company conduct a retrospective review of all invalidated OOS results conducted in the last three years, summarize the findings in a report, and develop a comprehensive CAPA for OOS investigation processes. 

Moving onto analytical methods, investigators found failures to verify methods used to analyze drug samples. Ultimately, FDA requested an independent assessment of all test methods to determine suitability and updated procedures for documenting said determination, method verification and validation timing and training records. 

Concerns About Data Integrity Lapses

The bulk of the Warning Letter concerned data integrity lapses, beginning with the aforementioned undocumented trial injection data. Investigators also found that electronic test data from high-performance liquid chromatography (HPLC) and gas chromatography (GC) systems lacked sufficient controls. Notably, analysts responsible for testing drug samples had the ability to delete raw files in the system. Audit trails were not enabled either. 

The audit trail issue was not addressed in the company’s 483 response. 

In the Warning Letter, FDA requested the company provide a detailed plan to enable audit trails as well as evaluate the effectiveness of the laboratory system, including documentation procedures, and ensure all HPLC and gas chromatography data undergoes Quality Unit review. 

Investigators found failures to verify methods used to analyze drug samples

In more strongly worded language, FDA stated that the quality system does not support good data integrity practice. This is what spurred FDA to recommend hiring a consultant. 

Further remediation requirements include:

  • An investigation into the issues cited above that encompasses a comprehensive methodology
  • Interviews with current and former employees by a third party
  • Assessments and evaluation of all data integrity deficiencies 
  • A risk assessment of the potential impact on test result quality (specifically any risk to patients)
  • A risk management strategy featuring details drawn from the CAPA

While the language is the standard boilerplate data integrity language, it is clear that significant lapses in data integrity occurred. Data integrity has become an increasingly cited issue by the Agency.

Not the First Data Integrity Rodeo

Interestingly, this was not the company’s first data integrity citation by FDA. In April 2016, FDA investigators Helen Verdel and Niketa Patel issued a 483. During an April 18-29, 2016 inspection, investigators found that “laboratory records do not include complete data derived from all tests, examinations and assay necessary to ensure compliance with established specifications and standards.”

In that instance, certain parameters were not saved in a specific analysis software. This meant data in the certificate of analysis could not be reproduced. Investigators cited three incidents of this occurring when analysts were testing raw materials. 

[NOTE: Looking to avoid a data integrity citation in a 483?  We can help!  Click here for a free 483 Observation Report using “data integrity” as your keyword.]

Get your 483 Observation Report

Changing Medical Device Regulations

Presented by Redica Systems 

What you will learn:

  • The latest developments regarding the EU MDR
  • Quality Systems requirements for medical devices
  • Regulatory updates affecting medical devices

Download the Special Report

Download your copy of THE FDA INSPECTION LANDSCAPE IN MID-2020 AND A LOOK AT VIRTUAL INSPECTION

In this summary we identify:

  • Trend analysis of FDA inspections through mid-2020
  • Strategies for preparing and hosting virtual inspections
  • New technologies to support remote inspections
Redica Systems Enforcement Analytics

Compare the enforcement history of your CDMOs.

Enter your email address and someone will contact you shortly to customize your report.

Redica Systems Enforcement Analytics

Monitor compliance at your Clinical Investigator sites.

Enter your email address and someone will contact you shortly to get you started.

Redica Systems Enforcement Analytics

Prepare for inspections of Clinical Investigator sites.

Enter your email address and someone will contact you shortly to provide more Clinical Investigator data about your sites.

Redica Systems Enforcement Analytics

Prepare for your next inspection.

Enter your email address and someone will contact you shortly to explore enforcement trends. 

Redica Systems Enforcement Analytics

Prepare for your next inspection.

Enter your email address and someone will contact you shortly to explore observations and trends. 

Redica Systems Enforcement Analytics

Prepare for your next inspection.

Enter your email address and someone will contact you shortly to run your custom report.

Redica Systems Enforcement Analytics

Get help choosing the right CRO.

Enter your email address and someone will contact you shortly to customize your insights.

Redica Systems Enforcement Analytics

Compare two companies of your choice.

Enter your email address and someone will contact you shortly to customize your report.

Download the Special Report

CDMO Comparison opt-in

In this summary we identify:

FY2018-FY2020 GMP data for Lonza & Catalent

Top GMP primary citations

Top FDA 483 observations

Redica Systems Enforcement Analytics

Evaluate Your CDMOs

Enter your email address and someone will contact you shortly to customize your report.

Panel Discussion – Remote Audits

Panel Discussion opt in image

Featuring Panelists:
—Barbara W. Unger, Unger Consulting, Inc.
—Jerry Chapman, Redica Systems
—Stephanie Gaulding, Pharmatech Associates

Who Will Benefit?
This session will be valuable to GMP quality, regulatory, compliance, and management personnel in FDA-regulated industries who want to have a conversation on remote audits and get to know what is going on in the industry.

Turning Failure into Success

Presented on Tuesday, April 27, 2021 by Steve Greer, Executive Coach, Genesis Assist, and former Quality Leader, Procter and Gamble

What you will learn:

  • How to use the Leadership SOS Model to transform quality culture
  • How to strengthen quality systems to eliminate human error
  • How to generate ideas on how to set your organization up for success for shareholders, FDA, and staff
Redica Systems Enforcement Analytics

Get Full Access to Redica Enforcement Analytics

Enter your email address and someone will contact you shortly to answer all of your questions and get you started.

Quality Management Systems for Small Pharma and Biotech Firms

Webinar: QMS for Small Pharma and Biotech Firms

Presented by Fenton Fong, Founder, Managing Director, & Principal at xCellarate

Get instant access to the webinar video and slides.

What you will learn:

  • Common challenges small pharma firms face when developing a QMS
    Recent enforcement trends involving the Quality Unit
    Impact of the COVID-19 pandemic

Download the Special Report

APAC ad

In this summary we identify:

GMP data from FY2017 to FY2020 for the Asia-Pacific region

Top 3 GMP primary and secondary citations

Top 3 483 observations

Download the Special Report

An Analysis Of MHRA’s Latest Annual GMP Inspection Deficiencies Report

In this summary we identify:

  • Data from 2019 UK MHRA Inspections
  • Trends from 2015, 2016, 2018, and 2019 inspections
  • Conclusions drawn from an analysis of drug inspection data

Experience the Power of Redica Systems

Redica_Vert_Periwinkle_RGB_Large

SEARCH Find the inspection records you want by inspector’s name, company name, site, city, country, etc.

WARNING LETTERS Easily search the largest database of FDA Warning Letters by date, company, FDA office, or subject

SITES Quickly assess inspection records including dates and inspectors across all of your sites

INSPECTIONS Complete list of FDA inspections by date, company, category, and country

Get Complete Access to the Redica Systems Platform

Please submit your email address and one of our team members will contact you shortly to answer all of your questions and get you started with the new Enforcement Analytics platform.

Redica Systems Enforcement Analytics

Compare the inspection history of your CDMO sites.

Enter your email address and someone will contact you shortly to customize your report.

Experience the Power of Redica Systems

Complete the form and one of our experts will reach out to you to schedule a demo and answer questions about our subscription options.

INDEX INFORMATION  Redica consolidates regulatory data in real-time on the single largest database for quality, safety, and compliance intelligence.

STRENGTHEN DATASETS Redica machine intelligence algorithms identify and triage risk signals to derive meaning from vast amounts of private and public data.

ANALYZE & INTERPRET PATTERNS Redica instantly models the customer-specific regulatory risks, trends, and opportunities that stand to fundamentally change compliance operations.

Download the Special Report

Combination Product Report

What You Will Learn from This Report:

The latest U.S. and European regulatory developments

The impact of smart combination products

How the EU MDR impacts drug-device combination products

Experience the Power of Redica Systems

Redica Systems Enforcement Analytics

Let us know who you are and we’ll be in touch to answer all of your questions and get you started.

Download the Special Report

5 GMP Case Studies Report

What You Will Learn from This Report:

In-depth analysis of the findings

Lessons learned

How companies can avoid similar shortcomings.

Experience the Power of Redica Systems

Redica Systems Expert Jerry Chapman to Present at SQA Annual Meeting

Index Information Redica consolidates regulatory data in real-time on the single largest database for quality, safety, and compliance intelligence.

Strengthen Datasets Redica machine intelligence algorithms identify and triage risk signals to derive meaning from vast amounts of private and public data.

Analyze & Interpret Patterns Redica instantly models the customer-specific regulatory risks, trends, and opportunities that stand to fundamentally change compliance operations.

Download the 510(k) Sample

What You Will Learn from This Sample:

See how a 510(k) submission is structured

Find out what information to include

Review correspondence between sponsor and FDA

Redica Systems Enforcement Analytics

Unlimited Access to Reports and Data

Enter your email address and someone will contact you shortly.

Download the Special Report

5 GMP Case Studies Report

What You Will Learn from This Report:

The first countrywide import alert issued by FDA

An inadequate deviation investigation

An inadequate product specifications and a product recall

Process validation issues at a CMO

A different perspective on process validation and the culpability of the quality unit

 

A.I. for Quality and Compliance Teams

August 3 webinar

Presented by Redica Systems Senior GMP Quality Expert Jerry Chapman

What you will learn:

  • A basic understanding of data sources, machine learning, NLP, and A.I. tools
  • Building and applying Expert Models
  • Two case studies, one on sterile manufacturing/503B and one on data integrity

Get the scoop on recent data integrity 483 observations!

  • FY 2020 Data Integrity 483 Observations
  • Data Integrity Observations for Human Drugs
  • Observations Falling Under GMP
  •  

Human Factors – Compliance and Applications

June webinar

Presented by Alison Sathe, Founder, Regulatory Mark & Valerie Fenster, Director of Insights and  Human Factors, Kaleidoscope Innovation 

What you will learn:

  • Human factors strategies from simple drug products to complex surgical devices
  • Primary and secondary labeling development and evaluation for usability
  • Human factors activities from product development to post-market
  • International strategies: expectations for human factors in regulatory submissions in international markets
Redica Systems Enforcement Analytics

Keep up with the latest Regulatory Developments on Clinical Trials

Enter your email address and someone will contact you shortly. 

Redica Systems Enforcement Analytics

Upgrade your inspection strategy.

Enter your email address and someone will contact you shortly to get the reports and analysis you need to prepare for your next inspection.

Redica Systems Enforcement Analytics

Save your team valuable time when using External Monitoring.

Enter your email address and someone will contact you shortly. 

Redica Systems Enforcement Analytics

Save time and Resources when using External Monitoring.

Enter your email address and someone will contact you shortly. 

Redica Systems Enforcement Analytics

Get immediate access to the news that matters to your sites.

Enter your email address and someone will contact you shortly. 

Redica Systems Enforcement Analytics

See how we can help you eliminate yet another spreadsheet.

Enter your email address and someone will contact you shortly. 

Redica Systems Enforcement Analytics

Stay ahead of changing regulations.

Enter your email address and someone will contact you shortly to get the data and analysis you need.

Redica Systems Enforcement Analytics

Upgrade your CDMO monitoring strategy.

Enter your email address and someone will contact you shortly to get the data and analysis you need.

Redica Systems Enforcement Analytics

Upgrade your CDMO management strategy.

Enter your email address and someone will contact you shortly to get the reports and analysis you need.

Experience the Power of Redica Systems

Redica Systems Enforcement Analytics

Sign up for your FREE account today and get instant access to Enforcement Analytics.

Redica Systems Enforcement Analytics

Upgrade your inspection strategy.

Enter your email address and someone will contact you shortly to get the reports and analysis you need.

Discover the power of the most comprehensive database of 483s in existence.

Our database of over 20,000 483s is retyped and tagged, making it easy to create an Observation Report in seconds.

Eliminate days of work and get your FREE personalized 483 Observation Report.